{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:23:15Z","timestamp":1782847395575,"version":"3.54.5"},"publisher-location":"Cham","reference-count":46,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031121838","type":"print"},{"value":"9783031121845","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/7854_2021_282","type":"book-chapter","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T09:50:22Z","timestamp":1642153822000},"page":"125-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach"],"prefix":"10.1007","author":[{"given":"Gabrielle","family":"Agin-Liebes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"issue":"2","key":"282_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday JS, Davis AK, Mitzkovitz CM, Bloesch EK, Davoli CC (2021) Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci 4(2):424\u2013435","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"282_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont\u00e9 KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S (2020) Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 34(2):155\u2013166","journal-title":"J Psychopharmacol"},{"issue":"8","key":"282_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00204-015-1513-x","volume":"89","author":"AM Ara\u00fajo","year":"2015","unstructured":"Ara\u00fajo AM, Carvalho F, Bastos MD, Pinho PG, Carvalho M (2015) The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 89(8):1151\u20131173","journal-title":"Arch Toxicol"},{"key":"282_CR4","volume-title":"Beck depression inventory (BDI-II)","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK (1996) Beck depression inventory (BDI-II). Pearson"},{"issue":"3","key":"282_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ (2019) REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev 71(3):316\u2013344","journal-title":"Pharmacol Rev"},{"issue":"6","key":"282_CR6","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109(6):2138\u20132143","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"282_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard J, Forbes B, Feilding A et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open label feasibility study. Lancet Psychiatry 3(7):619\u2013627","journal-title":"Lancet Psychiatry"},{"key":"282_CR8","doi-asserted-by":"crossref","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, Mcgonigle J, Nutt DJ (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 7(1)","DOI":"10.1038\/s41598-017-13282-7"},{"issue":"2","key":"282_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CM, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 235(2):399\u2013408","journal-title":"Psychopharmacology (Berl)"},{"issue":"15","key":"282_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of psilocybin versus escitalopram for depression. New Engl J Med 384(15):1402\u20131411","journal-title":"New Engl J Med"},{"issue":"4","key":"282_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cbpra.2014.01.007","volume":"21","author":"KC Collimore","year":"2014","unstructured":"Collimore KC, Rector NA (2014) Treatment of anxiety disorders with comorbid depression: a survey of expert CBT clinicians. Cogn Behav Pract 21(4):485\u2013493","journal-title":"Cogn Behav Pract"},{"issue":"11","key":"282_CR13","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1017\/S0033291711000900","volume":"41","author":"G Coull","year":"2011","unstructured":"Coull G, Morris PG (2011) The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic review. Psychol Med 41(11):2239\u20132252","journal-title":"Psychol Med"},{"issue":"1","key":"282_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/wps.20089","volume":"13","author":"P Cuijpers","year":"2014","unstructured":"Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF (2014) Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 13(1):56\u201367","journal-title":"World Psychiatry"},{"issue":"5","key":"282_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG et al (2021a) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78(5):481\u2013489","journal-title":"JAMA Psychiatry"},{"key":"282_CR16","doi-asserted-by":"crossref","unstructured":"Davis AK, Xin Y, Sepeda ND, Garcia-Romeu A, Williams MT (2021b) Increases in psychological flexibility mediate the relationship between acute psychedelic drug effects and decreases in racial trauma symptoms among people of color. Chron Stress:1\u201310","DOI":"10.1177\/24705470211035607"},{"key":"282_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.pbr.2018.07.008","volume":"242","author":"D De Gregorio","year":"2018","unstructured":"De Gregorio D, Enns JP, Nu\u00f1ez NA, Posa L, Gobbi G (2018) d-lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res 242:69\u201396","journal-title":"Prog Brain Res"},{"issue":"11","key":"282_CR18","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","volume":"60","author":"BN Gaynes","year":"2009","unstructured":"Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ (2009) What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60(11):1439\u20131445. https:\/\/doi.org\/10.1176\/ps.2009.60.11.1439","journal-title":"Psychiatr Serv"},{"issue":"02","key":"282_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.14m09298","volume":"76","author":"PE Greenberg","year":"2015","unstructured":"Greenberg PE, Fournier A-A, Sisitsky T, Pike CT, Kessler RC (2015) The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 76(02):155\u2013162. https:\/\/doi.org\/10.4088\/JCP.14m09298","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"282_CR20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197","journal-title":"J Psychopharmacol"},{"issue":"9","key":"282_CR21","first-page":"863","volume":"385","author":"G Gr\u00fcnder","year":"2021","unstructured":"Gr\u00fcnder G, Mertens L (2021) Psilocybin for depression. N Engl J Med 385(9):863","journal-title":"N Engl J Med"},{"key":"282_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fphar.2018.00897","volume":"9","author":"EC Haijen","year":"2018","unstructured":"Haijen EC, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, Nutt D, Daws RE, Hampshire AD, Lorenz R, Carhart-Harris RL (2018) Predicting responses to psychedelics: a prospective study. Front Pharmacol 9:897","journal-title":"Front Pharmacol"},{"issue":"4","key":"282_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.biopsych.2015.02.020","volume":"78","author":"JP Hamilton","year":"2015","unstructured":"Hamilton JP, Farmer M, Fogelman P, Gotlib IH (2015) Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience. Biol Psychiatry 78(4):224\u2013230","journal-title":"Biol Psychiatry"},{"issue":"12","key":"282_CR24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30(12):1259\u20131267","journal-title":"J Psychopharmacol"},{"issue":"4","key":"282_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","volume":"75","author":"DS Hasin","year":"2018","unstructured":"Hasin DS, Sarvet AL, Meyers JL et al (2018) Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 75(4):336. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4602","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"282_CR26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamapsychiatry.2019.1145","volume":"76","author":"BD Heifets","year":"2019","unstructured":"Heifets BD, Malenka RC (2019) Disruptive psychopharmacology. JAMA Psychiatry 76(8):775\u2013776","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"282_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10608-012-9476-1","volume":"36","author":"SG Hofmann","year":"2012","unstructured":"Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A (2012) The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res 36(5):427\u2013440","journal-title":"Cognit Ther Res"},{"issue":"1","key":"282_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.psychres.2005.10.009","volume":"145","author":"RW Iannuzzo","year":"2006","unstructured":"Iannuzzo RW, Jaeger J, Goldberg JF, Kafantaris V, Sublette ME (2006) Development and reliability of the HAM-D\/MADRS interview: an integrated depression symptom rating scale. Psychiatry Res 145(1):21\u201337","journal-title":"Psychiatry Res"},{"issue":"4","key":"282_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.31887\/DCNS.2011.13.4\/nkoen","volume":"13","author":"N Koen","year":"2011","unstructured":"Koen N, Stein DJ (2011) Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 13(4):423\u2013437","journal-title":"Dialogues Clin Neurosci"},{"issue":"2","key":"282_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","volume":"34","author":"LJ Mertens","year":"2020","unstructured":"Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL (2020) Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol 34(2):167\u2013180","journal-title":"J Psychopharmacol"},{"issue":"2","key":"282_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1017\/S1461145704004080","volume":"7","author":"DA Morilak","year":"2004","unstructured":"Morilak DA, Frazer A (2004) Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 7(2):193\u2013218. https:\/\/doi.org\/10.1017\/S1461145704004080","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 8","key":"282_CR32","first-page":"17","volume":"68","author":"CB Nemeroff","year":"2007","unstructured":"Nemeroff CB (2007) Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68(Suppl 8):17\u201325","journal-title":"J Clin Psychiatry"},{"key":"282_CR33","first-page":"482","volume-title":"The Oxford handbook of cognitive and behavioral therapies","author":"MW Otto","year":"2016","unstructured":"Otto MW, Hearon BA (2016) Combination treatment for anxiety and mood disorders: benefits and issues for the combination of cognitive-behavioral therapy and pharmacotherapy. In: The Oxford handbook of cognitive and behavioral therapies. Oxford University Press, New York, pp 482\u2013493"},{"issue":"5","key":"282_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0022167817711304","volume":"57","author":"J Phelps","year":"2017","unstructured":"Phelps J (2017 Sep) Developing guidelines and competencies for the training of psychedelic therapists. J Humanist Psychol 57(5):450\u2013487","journal-title":"J Humanist Psychol"},{"issue":"8","key":"282_CR35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"17","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 17(8):974","journal-title":"Front Pharmacol"},{"issue":"12","key":"282_CR36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis T, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga S, Belser A, Kalliontzi K, Babb J et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30(12):1165\u20131180","journal-title":"J Psychopharmacol"},{"issue":"5","key":"282_CR37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME (2003) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54(5):573\u2013583","journal-title":"Biol Psychiatry"},{"issue":"3","key":"282_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/070674371005500303","volume":"55","author":"M Sinyor","year":"2010","unstructured":"Sinyor M, Schaffer A, Levitt A (2010) The sequenced treatment alternatives to relieve depression (star*d) trial: a review. Can J Psychaitry 55(3):126\u2013135","journal-title":"Can J Psychaitry"},{"issue":"1","key":"282_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/bjp.167.1.99","volume":"167","author":"RP Snaith","year":"1995","unstructured":"Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P (1995) A scale for the assessment of hedonic tone the Snaith\u2013Hamilton Pleasure Scale. Br J Psychiatry 167(1):99\u2013103","journal-title":"Br J Psychiatry"},{"key":"282_CR40","first-page":"1","volume-title":"The Corsini encyclopedia of psychology","author":"CD Spielberger","year":"2010","unstructured":"Spielberger CD (2010) State-trait anxiety inventory. In: The Corsini encyclopedia of psychology, vol 30, p 1"},{"key":"282_CR41","doi-asserted-by":"publisher","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5:e12412","journal-title":"PLoS One"},{"issue":"1","key":"282_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry 163(1):28\u201340","journal-title":"Am J Psychiatry"},{"issue":"4","key":"282_CR43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","volume":"72","author":"ER Walker","year":"2015","unstructured":"Walker ER, McGee RE, Druss BG (2015) Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72(4):334. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2502","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"282_CR44","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R (2017) Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol 57(5):520\u2013564","journal-title":"J Humanist Psychol"},{"issue":"3","key":"282_CR45","first-page":"215","volume":"28","author":"MT Williams","year":"2021","unstructured":"Williams MT, Davis AK, Xin Y, Sepeda ND, Grigas PC, Sinnott S, Haeny AM (2021) People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs (Abingdon Engl) 28(3):215\u2013226","journal-title":"Drugs (Abingdon Engl)"},{"key":"282_CR46","unstructured":"World Health Organization. Depression fact sheet. World Health Organization. Published December 2019. Accessed 11 Jan 2020. http:\/\/www.who.int\/mediacentre\/factsheets\/fs369\/en\/"},{"issue":"2","key":"282_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2020","unstructured":"Yaden DB, Griffiths RR (2020) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci 4(2):568\u2013572","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["Current Topics in Behavioral Neurosciences","Disruptive Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2021_282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T20:07:52Z","timestamp":1661458072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2021_282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783031121838","9783031121845"],"references-count":46,"URL":"https:\/\/doi.org\/10.1007\/7854_2021_282","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"23 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}